Skip to content

Explore Grants

Recipient Purpose Term Amount
Brigham & Womens Hospital, Inc. To support the Program On Regulation, Therapeutics, and Law, which will evaluate the impact of drug innovation incentive policies. 2016 - 2017 $742,905
Brigham & Womens Hospital, Inc. To evaluate the impact of Pharmacy Benefits Managers on prescription drug pricing. 2017 - 2018 $77,315
Brigham & Womens Hospital, Inc. To support the Program On Regulation, Therapeutics, And Law. 2017 - 2020 $3,268,850
Center for Health Policy Development To support a working group of state health policy experts and stakeholders to examine emerging strategies for addressing the high cost of prescription drugs. 2016 - 2017 $146,271
Center for Health Policy Development To support the launch of the Center for Prescription Drug Price Action. 2017 - 2019 $2,021,350
Civica, Inc. To promote availability and affordability of essential generic drugs. 2018 - 2023 $1,000,000
Civica, Inc.** To promote availability and affordability of essential generic drugs. 2018 - 2030 $9,000,000
Doctors for America To develop a physician-centered coalition that will educate the public and key stakeholders about prescription drug pricing in the United States. 2019 - 2021 $552,596
Evidence for Healthcare Improvement To support the Institute for Clinical and Economic Review research that provides independent analyses of the comparative cost effectiveness for newly-introduced pharmaceutical drugs. 2017 - 2020 $13,966,892
Evidence for Healthcare Improvement To produce Institute for Clinical and Economic Review reports on new drugs that include information about a drug's comparative effectiveness, cost effectiveness, and potential budget impact. 2015 - 2017 $5,232,002
George Mason University Foundation, Inc. To develop and disseminate policy options related to the negotiation of prescription drug prices by Medicare. 2018 $37,475
Health Care For All Inc. To provide support for efforts to educate the public, policymakers, and key stakeholders about drug price increases, increase drug pricing transparency, and strengthen efforts to counter drug company marketing efforts. 2019 - 2020 $374,648
Henry J. Kaiser Family Foundation To examine trends in prescription drug prices and Medicare Part D formulary coverage and broadly disseminate the findings policy briefs, papers, and convenings. 2018 - 2020 $484,587
Henry J. Kaiser Family Foundation To provide researchers, policymakers, and the public with accessible, unbiased information about the Medicaid pharmacy benefit and policy options to lower Medicaid drug spending. 2019 - 2020 $423,447
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2016 - 2018 $1,060,500
Henry J. Kaiser Family Foundation To support Kaiser Health News in providing independent reporting on pharmaceutical drug development and pricing. 2017 - 2018 $200,000
Initiative for Medicines, Access, & Knowledge, Inc. To produce a report that will outline strategies to address pharmaceutical patents and pricing structures. 2016 $209,500
Initiative for Medicines, Access, & Knowledge, Inc. To support efforts to provide patients with affordable access to life-saving medications and improve public health. 2017 - 2019 $3,958,828
Johns Hopkins University To promote the adoption of a waste-free prescription drug formulary by private corporations in place of the current drug rebate system. 2018 - 2021 $940,607
Johns Hopkins University To increase the availability and affordability of life-saving drugs while maintaining incentives for innovation in drug development. 2015 - 2017 $318,000
Johns Hopkins University To develop research on policy options that maximize access to and affordability of prescription drugs. 2016 - 2019 $3,586,034
Kaiser Foundation Health Plan of Washington To evaluate a program designed to improve the value of pharmaceutical care. 2018 - 2021 $503,919
Louisiana Department of Health To support the development and launch of Louisiana's Hepatitis C subscription payment model to acquire Hepatitis C medication at an affordable cost for its Medicaid and correctional populations. 2019 - 2020 $939,766
Maryland Citizens Health Initiative Education Fund, Inc. To educate the public about a recently enacted law that prohibits price gouging in the sale of essential generic medications, along with other efforts states can take to impact rising drug costs. 2017 - 2019 $616,159
Arnold A decorative icon